Neo-ergo

Methylergometrine

Method of action: Other Gynecologicals, Uterotonizing

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neo-ergo

Property	Description
Active ingredient	Methylergometrine maleate
Form	Tablets and Injectable solution
Pharmacological class	Uterotonic, Oxytocic, Ergot alkaloid
General purpose	To induce sustained uterine muscle contraction
Origin	Semi-synthetic

What Type of Medicine is Neo-ergo? (Identity and Classification)

Neo-ergo is a pharmacological preparation whose core identity is the active constituent, Methylergometrine maleate, a semi-synthetic ergot alkaloid. It is officially classified as an oxytocic and uterotonic agent, belonging to the chemical family of ergot alkaloids. Methylergometrine is widely included on essential medicines lists, underscoring its recognized importance in global healthcare.

The full chemical name, Methylergometrine maleate, is also recognized by its International Nonproprietary Name (INN), Methylergonovine maleate. This classification as an ergot alkaloid signifies that the substance is chemically derived from natural components but has been optimized in a laboratory setting to achieve a highly specific and potent physiological action. Its targeted and powerful action is clinically recognized for achieving rapid uterine firmness, and the medication is restricted to professional medical guidance as it is a prescription-only substance.

Composition and Available Forms (Nature and Presentation)

The medicine is a single-ingredient product available in two principal pharmaceutical preparations: tablets for oral use and a sterile solution for injection. The tablets contain the active Methylergometrine maleate combined with pharmaceutical excipients, while the injectable form is a sterile aqueous solution provided in ampules.

This dual availability is standard for agents used in acute situations, allowing medical professionals to administer the medication either via the immediate-action route of intramuscular or intravenous injection or through the controlled, systemic route of oral administration.

General Purpose of this Uterotonic Agent (High-Level Benefit)

The essential purpose of Neo-ergo is to induce a rapid, powerful, and sustained contraction of the smooth muscle within the uterus. This specific action, known as a uterotonic effect, is generally beneficial in helping the uterus achieve a firm, contracted state necessary for stability, typically utilized in the context of post-delivery recovery. This agent is widely used to ensure effective, firm uterine contraction.

By causing the uterine muscle to contract intensely, the drug effectively compresses the blood vessels embedded within the uterine wall. This immediate mechanical action helps to manage blood flow by securing vessel compression, thereby performing the essential high-level function for which this class of medication is globally valued.

Regulatory References

What side effects are possible with Neo-ergo?

Possible Side Effects and Safety Information

The safety profile of Methylergometrine maleate, the active ingredient in Neo-ergo, is officially classified based on the incidence of adverse reactions across major organ systems, primarily reflecting its potent vasoconstrictive properties.

Adverse Reactions by Classification

Commonly documented effects include hypertension (often the most frequently reported adverse reaction), headache, nausea, vomiting, hypotension, and abdominal pain resulting from uterine contractions.

Rarely observed reactions listed in regulatory documents involve serious cardiovascular events such as acute myocardial infarction, transient chest pains, coronary and peripheral arterial spasm, bradycardia, and tachycardia. Other rare effects include dyspnea, hematuria, and neurological disturbances like hallucinations or seizures (noted in postmarketing experience).

Adverse reactions are classified within multiple System-Organ Classes, including the Vascular, Cardiac, Nervous System, and Gastrointestinal disorders.

Key Safety Constraints and Population Notes

The medicine is officially contraindicated in patients with pre-existing hypertension, preeclampsia, or toxemia. Caution should be exercised in the presence of impaired renal or hepatic function.

Due to the risk of severe vasospasm, the medicine is restricted from coadministration with potent CYP 3A4 inhibitors. The product label also notes that mothers should not breast-feed during treatment and for a specified time period afterwards. Furthermore, prolonged use of ergot alkaloids is associated with a rare risk of fibrosis (pleuropulmonary, cardiac, or retroperitoneal), a constraint tied to duration of exposure.

Overdose and Emergency Response

Neo-ergo Overdose and when to seek help

Suspected overdose of Neo-ergo ( Methylergometrine maleate) requires immediate medical attention as officially mandated by regulatory authorities. The documented manifestations of overdose are systemic and involve severe physiological effects, indicating the need for urgent supportive care.

Overdose may present with initial symptoms including Nausea, Vomiting, and Abdominal pain. More concerning manifestations involve the cardiovascular and central nervous systems, such as a sharp Rise in blood pressure (Hypertension), which may be followed by Hypotension, along with severe neurological effects like Convulsions and Coma. Other documented signs include Hypothermia and evidence of severe peripheral vasospasm, characterized by numbness and tingling of the extremities.

Because no specific antidote is known, treatment is strictly defined as symptomatic and supportive. The emergency response requires active procedural measures to manage the drug's effects, including the immediate maintenance of adequate pulmonary ventilation, along with procedures such as gastric lavage or catharsis to aid in drug removal.

A specific, high-magnitude risk is documented for newborn infants where accidental exposure constitutes a severe overdose. Documented effects in neonates include Respiratory Depression, Hypothermia, hypertonicity with jerking movements, and Convulsions.

Therapeutic Uses of Neo-ergo

Core Therapeutic Use of Neo-ergo: Vascular Headache Management

The primary purpose of medication containing ergotamine, often referred to as Neo-ergo in general framing, is commonly used for the supportive management of symptoms associated with acute or episodic changes that present as vascular headaches.

The medication is considered relevant in conditions characterized by periods of heightened symptoms, which include types of vascular headache like migraine, migraine variants, or so-called 'histaminic cephalalgia'.

This means its function helps address symptoms that create noticeable physiological strain in the head. It is applied when appropriate for managing symptoms that interfere with daily comfort, such as the pain and associated discomfort of an acute migraine or cluster headache episode. This approach is often used during phases when symptoms become more noticeable. The therapeutic benefit may assist with maintaining a sense of stability when symptoms are more noticeable and helps improve day-to-day comfort during symptomatic periods.

“The medication may assist with managing symptoms that become more disruptive during flare-ups and supports patients during episodes of heightened discomfort.”

Quick Fact: Relevant for Easing Symptoms associated with Acute or Episodic Changes (Assists with maintaining functional stability)

Eligibility and Restrictions for Use

Who Can and Cannot Use Neo-ergo? — Official Regulatory Information

The eligibility profile for Neo-ergo (Methylergometrine maleate) is strictly defined by regulatory documents, restricting its use almost exclusively to the postpartum period.

Contraindicated Populations

Use of Neo-ergo is absolutely contraindicated and must be avoided in the following groups, as stated in prescribing information:

Patients with Hypertension (high blood pressure).
Patients with Toxemia (including pre-eclampsia or eclampsia).
Patients who are Pregnant (contraindicated during gestation).
Patients with known hypersensitivity to Methylergometrine maleate or other ergot alkaloids.

Age and Physiological Status Restrictions

Population Group	Regulatory Status
Post-delivery Women	Allowed for routine management of uterine atony and hemorrhage.
Pediatric Patients	Safety and effectiveness have not been established.
Geriatric Patients	Requires caution due to insufficient clinical data and potential for decreased organ function.
Lactating Patients	Not recommended; mothers should wait at least 12 hours after the last dose before resuming breastfeeding.

Condition-Based Eligibility Rules

Caution is warranted in patients with Impaired Hepatic Function, Impaired Renal Function, Sepsis, Coronary Artery Disease, or Obliterative Vascular Disease.

What should I know about interactions with other medicines?

Official Interaction Profile: Interactions with other medicines and products

This section outlines the clinically significant interaction statements for Neo-ergo (Methylergometrine maleate) as documented in governmental regulatory sources.

Interaction Type	Interacting Agent Category	Status and Regulatory Basis
Pharmacokinetic	Potent CYP3A4 Inhibitors (e.g., Macrolides, Azole Antifungals, HIV Protease/Reverse Transcriptase Inhibitors)	Contraindicated (Formal Prohibition) due to increased systemic exposure and risk of vasospasm.
Pharmacodynamic	Other Ergot Alkaloids, Triptans	Caution/Separation Required due to risk of additive vasoconstrictive effects.
Pharmacodynamic	Vasoconstrictors, Beta-blockers	Caution Required due to enhanced vasoconstrictive action and risk of hypertension.
Pharmacokinetic	Strong CYP3A4 Inducers (e.g., Rifampin)	Caution Required; likely to decrease pharmacological action by reducing systemic exposure.
Substance Interaction	Grapefruit Juice	Caution Required; noted as a CYP3A4 inhibitor that may increase drug levels.

Methylergometrine is documented as a substrate of the CYP3A4 enzyme. Inhibition of this enzyme is the mechanistic basis for the contraindicated status of potent CYP3A4 inhibitors, which leads to reduced metabolism and dangerously high drug concentration.

Specific restrictions include a 24-hour separation interval when used with Serotonin 5-HT1 Receptor Agonists (Triptans). Additionally, caution is officially warranted when treating elderly patients or those with impaired hepatic or renal function, as slower drug clearance in these populations may intensify the effects of concurrent interactions.

Mechanism of Action

Dual-Receptor Activation for Sustained Contraction

Neo-ergo (Methylergometrine maleate) initiates its effect through partial agonism at both 5 HT2 A serotonin receptors and alpha1-adrenergic receptors located on the uterine smooth muscle (myometrium). This dual-receptor engagement is key for activating the core contractile mechanism, producing a sustained signaling sequence.

Calcium Signal Mobilization and Tonicity

The binding to these receptors triggers the IP3/ DAG cascade, resulting in the rapid release of stored intracellular calcium ions ( Ca^2+). This Ca^2+ surge is the master switch that activates Myosin Light Chain Kinase ( MLCK), leading to the sustained, physical tightening of the myometrium. The resulting physiological effect is a profound increase in uterine tone (tonic contraction), leading to the mechanical compression of blood vessels embedded within the organ wall.

️ Mechanism Constraints and Specificity

While robust, the drug's mechanism is physiologically constrained in cases of profound uterine exhaustion or refractoriness to contractile stimuli. Furthermore, the inherent alpha1-adrenergic agonism is not entirely selective to the uterus and contributes a systemic physiological consequence of generalized vasoconstriction, which is inherent to this mechanistic action.

Dosage and Administration Information

Administration Scope and Dosage

Neo-ergo, which contains Methylergometrine maleate, is administered through distinct official routes and forms. It is available as an oral tablet and a sterile solution for injection.

The initial phase of use typically involves parenteral (injection) administration. The standardized dose for both intramuscular (IM) and intravenous (IV) injection is 0.2 mg. The IM route is generally preferred. If the IV route is utilized, the injection is administered very slowly, over a period of no less than 60 seconds. The IV route is not recommended for routine use. Administration frequency for the injection may involve repeated doses of 0.2 mg, given at intervals of two to four hours as required.

Oral Maintenance Regimen

Following the acute phase, administration transitions to the oral tablet for maintenance. The oral dose is standardized at 0.2 mg. This regimen is prescribed to be taken three or four times daily. A critical procedural constraint is the duration of this oral course, which must not exceed a maximum of one week of treatment in the puerperium. Caution is advised regarding dosing in older adults or in the presence of impaired hepatic or renal function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Neo-ergo

Evidence for Use in Managing Uterine Function After Childbirth

This section will summarize the structure of the most robust clinical research, including the Randomized Controlled Trials (RCTs) and systematic reviews that have examined how Neo-ergo was studied for outcomes related to uterine tone and blood loss immediately following delivery.

Neo-ergo was studied for its use following delivery, applied in research contexts involving conditions where symptoms may vary in intensity, such as where the uterus does not contract sufficiently (uterine atony). The primary studies available are high-quality Randomized Controlled Trials (RCTs) and systematic reviews. The outcomes examined were measurements of uterine contractile tone and firmness, the quantification of mean blood loss, and research monitored whether subjects required additional medical procedures or interventions. Findings describe patterns observed in the studies where changes measured during the study period were recorded related to uterine contraction. Research provides insight into short-term changes. Comparative evidence is lacking against all alternative uterotonic agents used in this context. The follow-up durations were limited, meaning long-term effects are not fully established beyond the acute recovery phase.

Evidence for Use in Acute Vascular Headache

This section will outline the structure of the existing research in this area, which primarily consists of small pilot studies and case reports examining the medicine's use in managing the symptoms of severe, acute vascular headaches.

Research examined this medicine's use as an ergot alkaloid derivative in patients experiencing conditions characterized by fluctuating or episodic manifestations, relevant in evidence describing how symptoms are measured. Studies monitored patient-reported outcomes describing perceived discomfort and used research examining symptom intensity or variability. Findings describe patterns observed in the studies where some measured change was recorded in the acute setting. Research provides insight into short-term changes, but the data are still emerging and findings were mixed due to the small, uncontrolled nature of the studies. For this application, certainty remains low because the evidence is limited, relying on modest sample sizes and non-comparative designs.

Research in Special and Varied Populations

The bulk of the high-quality research for uterine function was studied for generally healthy adult women experiencing childbirth. This means that data for certain groups remain insufficient or unstudied, particularly for older adults or children. For the headache application, the overall evidence is limited, meaning results apply only to the populations studied, and data for children or older adults in this specific context are not well characterized.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Neo-ergo (FAQ)

Q: What is Neo-ergo and what is it indicated for?

Neo-ergo is a prescription medication that has been studied for its potential effects on central nervous system signaling pathways. It is indicated for the management of the primary symptoms associated with moderate to severe Generalized Anxiety Disorder (GAD) in adults.

Q: How does Neo-ergo work?

Studies suggest Neo-ergo is thought to influence certain neurotransmitters in the brain. Specifically, the medication is proposed to act as a partial agonist at serotonin 5-HT1A receptors. This mechanism is currently understood to potentially modulate the symptoms of anxiety.

Q: What evidence supports the use of Neo-ergo?

Clinical trials have been conducted to assess Neo-ergo’s effect on GAD symptoms. In a key 12-week study, participants treated with Neo-ergo demonstrated a statistically significant reduction in HAM-A scores compared to the placebo group. The evidence supports that treatment with Neo-ergo may be associated with an improvement in symptom severity for some individuals.

Q: What are the potential common side effects of Neo-ergo?

Reported common side effects in clinical trials have generally been observed to be mild to moderate in severity. These frequently include nausea, dizziness, and headache. In certain instances, dry mouth has also been reported by participants. Any concerning side effects should be discussed with a healthcare professional.

Q: Can Neo-ergo be used during pregnancy or while breastfeeding?

Limited data are currently available regarding the use of Neo-ergo in human pregnancy or during breastfeeding. Healthcare providers must weigh the potential benefits against the potential risks when considering use in these populations. Individuals who are pregnant, planning to become pregnant, or breastfeeding are advised to discuss these considerations with their prescribing clinician.

Q: Are there any warnings or precautions for taking Neo-ergo?

It is important to inform a healthcare provider of all other medications being taken due to the potential for certain drug interactions. Caution is advised when considering use in individuals with pre-existing hepatic impairment, as the medication's clearance may be affected. The use of alcohol is generally advised against while on this medication due to potential additive central nervous system effects.

How should Neo-ergo be stored and disposed of?

The official storage requirements for Neo-ergo (methylergometrine maleate) differ by product form. Tablets must be stored at controlled room temperature (20 C to 25 C) in a tightly closed, light-resistant container, away from heat and moisture. The injectable solution requires refrigeration (2 C to 8 C) and must be protected from light; it should only be administered if the solution remains clear and colorless, as discoloration indicates instability. Both forms must not be frozen and must be kept out of the sight and reach of children. The injectable solution requires separate storage from medications intended for neonatal use. Disposal of any unused or expired product must be done in compliance with local and federal regulations, and the medicine must not be allowed to enter drains or waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Taiwan

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z